Anticancer Potential of Pyridoxine-Based Doxorubicin Derivatives: An In Vitro Study.
Karwt R, Bondar OV, Pugachev MV, Mohammad T, Kadyrova AS, Pavelyev RS, Alrhmoun S, Gnezdilov OI, Shtyrlin YG.
Karwt R, et al.
Life (Basel). 2024 Feb 20;14(3):282. doi: 10.3390/life14030282.
Life (Basel). 2024.
PMID: 38541608
Of these two compounds, DOX-2, in which the pyridoxine fragment is attached to the doxorubicin molecule via a C3 linker, revealed higher selectivity against specific cancer cell types compared to doxorubicin and a promising safety profile for conditionally normal cells. .. …
Of these two compounds, DOX-2, in which the pyridoxine fragment is attached to the doxorubicin molecule via a C3 linker, revealed hig …